Free Trial
Jonathan Chang

Jonathan Chang Analyst Performance

Senior Research Analyst at Leerink Partners

Jonathan Chang is a stock analyst at Leerink Partners, covering 8 publicly traded companies across a range of sectors. Over the past year, Jonathan Chang has issued 3 stock ratings, including buy and hold recommendations. While full access to Jonathan Chang's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Jonathan Chang's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
12 Last 7 Years
Buy Recommendations
83.33% 10 Buy Ratings
Companies Covered
8 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy83.3%10 ratings
Hold16.7%2 ratings
Sell0.0%0 ratings

Out of 12 total stock ratings issued by Jonathan Chang at Leerink Partners, the majority (83.3%) have been Buy recommendations, followed by 16.7% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
8 companies

Jonathan Chang, an analyst at Leerink Partners, currently covers 8 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
8 companies
100.0%

Jonathan Chang of Leerink Partners specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
5 companies
62.5%
MED - DRUGS
1 company
12.5%
BIOTECHNOLOGY
1 company
12.5%
PHARMACEUTICAL PREPARATIONS
1 company
12.5%

About Jonathan Chang

Jonathan Chang, Ph.D., CFA is a Senior Research Analyst at Leerink Partners covering Emerging Oncology. He has been an important contributor to the Firm’s biotechnology research product and insights. Jonathan joined the Firm in 2013 as an Associate supporting the Firm’s senior oncology biotechnology research team and in 2016, he assumed research coverage of several important emerging biotechnology companies. In 2018, he was named a Rising Star in Institutional Investor’s 2018 All-America Research Team for Biotechnology/Mid- & Small-Cap. He earned a Ph.D. in Pharmacology from Cornell University, an M.A. in Biotechnology from Columbia University, and an Honors B.Sc. in Genes, Genetics, and Biotechnology from the University of Toronto. Dr. Chang is a CFA charter holder.

Jonathan Chang's Ratings History at Leerink Partners

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Replimune Group, Inc. stock logo
REPL
Replimune Group
7/22/2025Reiterated Rating$2.96$3.00Market Perform
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
6/30/2025Set Price Target$34.79$75.00Outperform
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2/13/2025Upgrade$19.69$27.00Outperform